xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

441

Orlandi et al.

(Continues)

Anti-TNF- α therapy can be associated with new-onset RS, mainly CRSsNP. Modification of anti-TNF- α therapy

nasopharyngitis and upper respiratory tract infection. IqYmune R was shown to be effective and well tolerated in patients with primary immunodeficiency.

Overall, 228 infections were reported, most frequently bronchitis, CRS,

Ig replacement therapy has a positive impact on the frequency of RS and confirm its positive impact on

pulmonary infections in adult patients with CVID and SAD.

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Chiarella 1289 2017 4 Literature review In those patients with frequent CRS exacerbations or who are refractory to Krivan 1286 2017 4 Multi-center, open-label,

treatment, an immunodeficiency evaluation should be considered. Treatment includes vaccination,

antibiotic therapy, Ig replacement and surgery.

should be considered as an option in the medical management of these patients.

Nayan 1287 2015 4 Literature review High clinical suspicion of primary immunodeficiency must be maintained in the setting of refractory CRS. Early

diagnosis and management of PID has a significant impact on their overall morbidity and QoL.

bacterial infections/patient.

post-treatment

Lund-Mackay scores, and frequency of RS and pulmonary infections requiring rescue antibiotics.

Patient demographics, RS characteristics, and treatment course.

Annualized rate of serious

Wang 1291 2017 4 Retrospective review 28 patients on a TNF- α inhibitor diagnosed with RS

A highly purified 10% polyvalent immunoglobulin preparation (IqYmune R ) for IV administration in patients with primary immunodeficiency was

administered to 62 patients (aged 2-61 years) with X-linked

agammaglobulinemia or CVID

prospective, single armstudy

Walsh 931 2017 4 Retrospective review 31 patients with CVID and SAD Pretreatment and

TABLE IX-44 (Continued)